March's edition of the EJHP includes an editorial on "Value or cost", and original articles on: evaluation of a pharmaceutical assessment screening tool; biosimilar infliximab for the management of rheumatoid arthritis; the cost and efficiency of incident reporting in a specialist paediatric NHS hospital and impact on patient safety; ready-to-use parenteral amiodarone; and much more.

The edition also contains a case report on bradycardia associated with pegylated liposomal doxorubicin administration, as well as a postcript on deprescribing in India: will we ever get down to it?.